Previous 10 | Next 10 |
Enrollment Completed in CAHptain-205 Study in Pediatric Classic Congenital Adrenal Hyperplasia (CAH) Target Enrollment Completed in CAHmelia-203 Study in Adult Classic CAH CAHmelia-204 Study in Adult Classic CAH on Track to Complete Enrollment in Early Q1 2024 Spruce B...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Spruce Biosciences Inc. (SPRB) is expected to report $-0.34 for Q3 2023
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in the Jefferies London Healthcar...
Final Enrollment in CAHmelia-203 to Exceed Target Due to Substantial Patient Interest CAHmelia-203 Topline Results Anticipated in the First Quarter of 2024 CAHmelia-204 Completion of Enrollment Anticipated in Early First Quarter of 2024 Spruce Biosciences, Inc. (Nasd...
2023-09-12 14:05:37 ET More on Spruce Seeking Alpha’s Quant Rating on Spruce Biosciences Historical earnings data for Spruce Biosciences Financial information for Spruce Biosciences Spruce Biosciences: H2 2023 Data Could Be A Game Changer For CAH Treat...
Spruce Biosciences, Inc. (NASDAQ: SPRB) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 11.92% on the day to $2.55. Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing n...
2023-09-12 10:11:31 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...
2023-09-12 08:41:35 ET Summary Results from the phase 2b CAHmelia-203 clinical trial, which is using tildacerfont for the treatment of patients with classic congenital adrenal hyperplasia, expected in the 2nd half of 2023. Results from the CAHptain study, using tildacerfont for th...
2023-09-08 09:48:18 ET More on Spruce Seeking Alpha’s Quant Rating on Spruce Biosciences Historical earnings data for Spruce Biosciences Financial information for Spruce Biosciences Sizing Up Spruce Biosciences For further details see: Spru...
News, Short Squeeze, Breakout and More Instantly...
Spruce Biosciences Inc. Company Name:
SPRB Stock Symbol:
NASDAQ Market:
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will presen...
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that three submitted abstracts were accepted for the 106 th Annual ...
Analyses of Data from CAHmelia-203 in Adult Congenital Adrenal Hyperplasia (CAH) Demonstrate Correlation Between Tildacerfont Response and Baseline Glucocorticoid (GC) Dose and Drug Compliance Posters Highlighting Baseline Characteristics from the CAHmelia Program in Adult CAH and CAHptai...